Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor ImmunityEva Sum, Pablo Umaña, Moritz Rapp et al.|Clinical Cancer Research|2021Cited by 70
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBsOmar Abdelmotaleb, Christian Klein, Tijana Nikić et al.|mAbs|2025Cited by 2
Abstract 1235: Impact of anti-CD3 and tumor-target binder affinities on <i>in-vitro</i> potency, <i>in-vivo</i> efficacy, and cytokine releaseOmar Abdelmotaleb, Christian Klein, Anneliese Schneider et al.|Cancer Research|2024Cited by 1
Supplementary Table 2 from Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor ImmunityEva Sum, Pablo Umaña, Moritz Rapp et al.|Unknown|2023Cited by 0
Supplementary material and methods from Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor ImmunityEva Sum, Pablo Umaña, Moritz Rapp et al.|Unknown|2023Cited by 0